Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Dextropropoxyphene measurement |
Has measured component (attribute) |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Dextropropoxyphene measurement |
Component |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Product containing propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Product containing aspirin and caffeine and propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
|
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
1 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
3 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
3 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
3 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
3 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely dextropropoxyphene hydrochloride 32.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely dextropropoxyphene hydrochloride 32.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Some |
2 |